Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

Mutations in the tumor-suppressor genes BRCA1 and BRCA2 resulting in BRCA1/2
deficiency are frequently identified in breast, ovarian, prostate, pancreatic, and other …

Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …

Background Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are
targeted therapies approved for homologous recombination repair (HRR)-deficient breast …

In recent years, various poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have
been approved for the treatment of several cancers to target the vulnerability of homologous …

Drug resistance is a principal limitation to the long-term efficacy of cancer therapies. Cancer
genome sequencing can retrospectively delineate the genetic basis of drug resistance, but …

An important advance in cancer therapy has been the development of poly (ADP-ribose)
polymerase (PARP) inhibitors for the treatment of homologous recombination (HR)-deficient …

Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …

Purpose: We evaluated the activity of AZD8205, a B7-H4–directed antibody–drug conjugate
(ADC) bearing a novel topoisomerase I inhibitor (TOP1i) payload, alone and in combination …

PARP1 and PARP2 detect DNA breaks, which activates their catalytic production of poly
(ADP-ribose) that recruits repair factors and contributes to PARP1/2 release from DNA …